Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
McKinsey
Cerilliant
Covington
Healthtrust
Baxter
Queensland Health
US Army
Express Scripts
Cantor Fitzgerald

Generated: January 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,559,158

« Back to Dashboard

Which drugs does patent 6,559,158 protect, and when does it expire?

Patent 6,559,158 protects RELISTOR and is included in two NDAs.

This patent has seven patent family members in six countries.
Summary for Patent: 6,559,158
Title: Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
Abstract:A method of preventing or treating an opioid-induced side effect in a patient who has been chronically taking opioids, the method comprising administering a quaternary derivative of noroxymorphone in an amount sufficient to prevent or treat the side effect in the patient, but which amount would be insufficient to treat a patient with the same opioid-induced side effect who had not chronically been administered opioids.
Inventor(s): Foss; Joseph F. (Chicago, IL), Roizen; Michael F. (Chicago, IL), Moss; Jonathan (Chicago, IL), Yuan; Chun-Su (Chicago, IL), Drell; William (San Diego, CA)
Assignee: UR Labs, Inc. (Reno, NV) The University of Chicago (Chicago, IL)
Application Number:09/669,358
Patent Claim Types:
see list of patent claims
Use; Delivery;

Drugs Protected by US Patent 6,559,158

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Salix Pharms RELISTOR methylnaltrexone bromide SOLUTION;SUBCUTANEOUS 021964-002 Sep 27, 2010 RX Yes Yes ➤ Subscribe ➤ Subscribe TREATMENT OF OPIOID-INDUCED CONSTIPATION ➤ Subscribe
Salix Pharms RELISTOR methylnaltrexone bromide SOLUTION;SUBCUTANEOUS 021964-001 Apr 24, 2008 RX Yes Yes ➤ Subscribe ➤ Subscribe TREATMENT OF OPIOID-INDUCED CONSTIPATION ➤ Subscribe
Salix Pharms Inc RELISTOR methylnaltrexone bromide TABLET;ORAL 208271-001 Jul 19, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe TREATMENT OF OPIOID-INDUCED CONSTIPATION ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,559,158

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,972,954 Use of methylnaltrexone and related compounds ➤ Subscribe
6,274,591 Use of methylnaltrexone and related compounds ➤ Subscribe
6,608,075 Use of methylnaltrexone and related compounds ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,559,158

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 467415 ➤ Subscribe
Australia 1380299 ➤ Subscribe
Australia 758416 ➤ Subscribe
Canada 2312234 ➤ Subscribe
Germany 69841663 ➤ Subscribe
European Patent Office 1047426 ➤ Subscribe
World Intellectual Property Organization (WIPO) 9922737 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Medtronic
Teva
Farmers Insurance
QuintilesIMS
Dow
Cerilliant
Cipla
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot